SR-202: Selective PPARγ Antagonist for Precision Metabolic Research

Executive Summary: SR-202 (PPAR antagonist) is a chemically defined tool for selective inhibition of PPARγ, a nuclear receptor central to glucose and lipid metabolism (APExBIO). In vitro and in vivo studies confirm that SR-202 blocks TZD-induced coactivator recruitment and PPARγ transcriptional activity, inhibiting adipocyte differentiation (Bays 2011, DOI:10.1002/kjm2.12927). Treatment with SR-202 in murine models reduces high fat diet-induced adipocyte hypertrophy and insulin resistance, and normalizes plasma TNF-α (APExBIO datasheet). No clinical trials have been reported. SR-202 is provided as a white solid, soluble in DMSO, ethanol, and water at ≥50 mg/mL, and should be stored desiccated at room temperature (SR-202, APExBIO).

Biological Rationale

Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated nuclear receptor that controls glucose uptake, fatty acid storage, and adipocyte differentiation (Xue et al. 2025). Activation of PPARγ promotes adipogenesis and insulin sensitivity, while its inhibition is associated with reduced adipocyte formation and improved metabolic profiles in animal models. Selective antagonists like SR-202 enable targeted dissection of PPAR signaling in preclinical obesity and type 2 diabetes research. SR-202 allows researchers to study the consequences of PPARγ inhibition on macrophage polarization, adipogenic gene expression, and systemic metabolic homeostasis. This mechanistic insight is critical for anti-obesity drug development and for modeling insulin resistance in metabolic syndrome (see this guide for protocol optimization; this article extends the mechanistic rationale for immune-metabolic crosstalk).

Mechanism of Action of SR-202 (PPAR antagonist)

SR-202 specifically antagonizes PPARγ by blocking thiazolidinedione (TZD)-stimulated recruitment of steroid receptor coactivator-1 (SRC-1), suppressing PPARγ transcriptional activity (APExBIO). In cell culture, SR-202 inhibits both hormone- and TZD-induced adipocyte differentiation. It does not significantly affect unrelated nuclear receptors (SR-202 comparative analysis; this article clarifies selectivity benchmarks for nuclear receptor panels). In vivo, SR-202 reduces adipocyte hypertrophy and insulin resistance in high-fat diet and obese mouse models. Its antagonistic activity also modulates macrophage polarization, shifting the balance toward reduced pro-inflammatory M1 and increased anti-inflammatory M2 phenotypes (Xue et al. 2025).

Evidence & Benchmarks

• SR-202 inhibits TZD-induced recruitment of coactivator SRC-1, blocking PPARγ transcriptional activation in vitro (APExBIO datasheet).
• SR-202 selectively antagonizes PPARγ with minimal cross-reactivity to other nuclear receptors (SR-202: Selective PPARγ Antagonist).
• In murine models, SR-202 reduces high fat diet-induced adipocyte hypertrophy and improves insulin sensitivity (APExBIO).
• SR-202 treatment reverses elevated plasma TNF-α in wild-type mice on a high-fat diet (APExBIO).
• Activation (not antagonism) of PPARγ regulates M1/M2 macrophage polarization and attenuates inflammatory bowel disease via STAT-1/STAT-6 pathways (Xue et al. 2025).

Applications, Limits & Misconceptions

Applications:

• Modeling PPAR-dependent adipocyte differentiation inhibition in vitro and in vivo.
• Dissecting PPAR signaling in obesity research, type 2 diabetes, and immunometabolic disorders.
• Studying macrophage polarization and metabolic-immune cross-talk (SR-202: Macrophage Immunometabolic Profiling; this article updates mechanistic boundaries for immune intervention).

Limits:

• SR-202 has not been evaluated in human clinical trials; all efficacy and safety data are preclinical.
• Long-term storage of SR-202 solutions is not recommended due to potential instability (APExBIO).
• SR-202 is not intended for direct therapeutic use in humans.

Common Pitfalls or Misconceptions

• SR-202 does not activate PPARγ; it is strictly an antagonist and cannot substitute for agonists in upregulation studies.
• It does not block all nuclear receptors—selectivity is demonstrated for PPARγ with limited effect on PPARα/δ or unrelated receptors.
• SR-202 cannot be used for clinical treatment or diagnosis; its role is restricted to laboratory research.
• Sustained storage of prepared solutions (>7 days) may result in compound degradation; fresh solutions are recommended.
• Effects in murine models do not guarantee translation to human physiology without additional validation.

Workflow Integration & Parameters

SR-202 is supplied as a white solid with a molecular weight of 358.65 and formula C₁₁H₁₇ClO₇P₂. It is soluble at ≥50 mg/mL in DMSO, ethanol, and water. Recommended storage is desiccated at room temperature, with immediate use of prepared solutions. Dosing regimens in murine studies typically range from 1–10 mg/kg/day, administered via intraperitoneal injection or oral gavage; in vitro working concentrations are commonly 1–10 μM, depending on assay sensitivity (SR-202 (PPAR antagonist), APExBIO). For detailed stepwise protocols and troubleshooting, see this article (which offers actionable guidance for workflow integration and expands on translational strategy).

Conclusion & Outlook

SR-202, available from APExBIO (SKU B6929), is a validated tool for selective PPARγ inhibition in preclinical metabolic and immunometabolic research. Its unique selectivity profile and robust activity in cellular and animal models make it a key reagent for dissecting the PPAR signaling pathway, insulin resistance, and adipocyte biology. While translational promise is substantial, future work must address species-specific responses and long-term safety before considering clinical investigation. For more information and ordering details, visit the official SR-202 product page.